These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15334308)

  • 1. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
    Miyachi H
    IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
    Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
    Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
    Sierra ML; Beneton V; Boullay AB; Boyer T; Brewster AG; Donche F; Forest MC; Fouchet MH; Gellibert FJ; Grillot DA; Lambert MH; Laroze A; Le Grumelec C; Linget JM; Montana VG; Nguyen VL; Nicodème E; Patel V; Penfornis A; Pineau O; Pohin D; Potvain F; Poulain G; Ruault CB; Saunders M; Toum J; Xu HE; Xu RX; Pianetti PM
    J Med Chem; 2007 Feb; 50(4):685-95. PubMed ID: 17243659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
    Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
    Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor.
    Wurch T; Junquero D; Delhon A; Pauwels J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):133-40. PubMed ID: 11819031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
    Asaki T; Aoki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
    Bioorg Med Chem; 2008 Jan; 16(2):981-94. PubMed ID: 17964792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes.
    Barbier O; Fontaine C; Fruchart JC; Staels B
    Trends Endocrinol Metab; 2004 Sep; 15(7):324-30. PubMed ID: 15350604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes.
    Mazzucotelli A; Viguerie N; Tiraby C; Annicotte JS; Mairal A; Klimcakova E; Lepin E; Delmar P; Dejean S; Tavernier G; Lefort C; Hidalgo J; Pineau T; Fajas L; Clément K; Langin D
    Diabetes; 2007 Oct; 56(10):2467-75. PubMed ID: 17646210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
    Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
    Grau R; Punzón C; Fresno M; Iñiguez MA
    Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.